M
Marco Filetti
Researcher at Sapienza University of Rome
Publications - 87
Citations - 1860
Marco Filetti is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 63 publications receiving 888 citations. Previous affiliations of Marco Filetti include Helsinki Institute for Information Technology & University of Kent.
Papers
More filters
Journal ArticleDOI
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
Alessio Cortellini,Melissa Bersanelli,Sebastiano Buti,Katia Cannita,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Maria Michiara,Pietro Di Marino,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Francesca Rastelli,Federica Pergolesi,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Andrea De Giglio,Daniela Iacono,Alain Gelibter,Mario Occhipinti,Alessandro Parisi,Giampiero Porzio,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella,Clara Natoli +44 more
TL;DR: Overweight could be considered a tumorigenic immune-dysfunction that could be effectively reversed by ICIs and BMI could be a useful predictive tool in clinical practice and a stratification factor in prospective clinical trials with ICIs.
Journal ArticleDOI
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Daniele Marinelli,Marco Mazzotta,Stefano Scalera,Irene Terrenato,Francesca Sperati,L. D'Ambrosio,Matteo Pallocca,Giacomo Corleone,Eriseld Krasniqi,L. Pizzuti,Maddalena Barba,Silvia Carpano,Patrizia Vici,Marco Filetti,Raffaele Giusti,Andrea Vecchione,Mario Occhipinti,Alain Gelibter,Andrea Botticelli,F De Nicola,Ludovica Ciuffreda,Frauke Goeman,Enzo Gallo,Paolo Visca,Edoardo Pescarmona,Maurizio Fanciulli,R De Maria,Paolo Marchetti,Gennaro Ciliberto,Marcello Maugeri-Saccà +29 more
TL;DR: It is indicated that coexisting alterations in a limited set of genes characterize a subset of LUAD unresponsive to immunotherapy and with high TMB, which may account for the clinical course of the disease.
Journal ArticleDOI
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study
Alessio Cortellini,Sebastiano Buti,Daniele Santini,Fabiana Perrone,Raffaele Giusti,Marcello Tiseo,Melissa Bersanelli,Maria Michiara,Antonino Grassadonia,Davide Brocco,Nicola Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Riccardo Marconcini,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Gian Carlo Antonini Cappellini,Federica De Galitiis,Maria Giuseppa Vitale,Roberto Sabbatini,Sergio Bracarda,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Rita Chiari,Biagio Ricciuti,Daniela Iacono,Maria Rita Migliorino,Antonio Rossi,Giampiero Porzio,Katia Cannita,Valeria Ciciarelli,Maria Concetta Fargnoli,Paolo A. Ascierto,Corrado Ficorella +44 more
TL;DR: The finding of a greater incidence of irAEs among female patients ranks among the "hot topics" in gender-related differences in immuno-oncology.
Journal ArticleDOI
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
Alessio Cortellini,Marco Tucci,Vincenzo Adamo,Luigia Stefania Stucci,Alessandro Russo,Enrica Teresa Tanda,Francesco Spagnolo,Francesca Rastelli,R. Bisonni,Daniele Santini,Marco Russano,Cecilia Anesi,Raffaele Giusti,Marco Filetti,Paolo Marchetti,Andrea Botticelli,Alain Gelibter,Mario Occhipinti,Riccardo Marconcini,Maria Giuseppa Vitale,Linda Nicolardi,Rita Chiari,Claudia Bareggi,Olga Nigro,Alessandro Tuzi,Michele De Tursi,Nicola Petragnani,Laura Pala,Sergio Bracarda,Serena Macrini,Alessandro Inno,Federica Zoratto,Enzo Veltri,Barbara Di Cocco,Domenico Mallardo,Maria Grazia Vitale,David J. Pinato,Giampiero Porzio,Corrado Ficorella,Paolo A. Ascierto +39 more
TL;DR: The association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors is confirmed, which can be assumed to have immune-modulating detrimental effects.
Journal ArticleDOI
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Alessio Cortellini,Rita Chiari,Biagio Ricciuti,Giulio Metro,Fabiana Perrone,Marcello Tiseo,Melissa Bersanelli,Paola Bordi,Daniele Santini,Raffaele Giusti,Antonino Grassadonia,Pietro Di Marino,N. Tinari,Michele De Tursi,Federica Zoratto,Enzo Veltri,Francesco Malorgio,Carlo Garufi,Marco Russano,Cecilia Anesi,Tea Zeppola,Marco Filetti,Paolo Marchetti,Rossana Berardi,Silvia Rinaldi,Marianna Tudini,Rosa Rita Silva,Annagrazia Pireddu,Francesco Atzori,Daniela Iacono,Maria Rita Migliorino,Giampiero Porzio,Katia Cannita,Corrado Ficorella,Sebastiano Buti +34 more
TL;DR: It is confirmed that irAEs are concordantly related to higher ORR, longer PFS, and longer OS with anti-PD-1 immunotherapy in patients with NSCLC.